Insmed Inc [INSM] stock is trading at $127.8, up 0.04%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The INSM shares have gain 16.66% over the last week, with a monthly amount glided 22.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Insmed Inc [NASDAQ: INSM] stock has seen the most recent analyst activity on August 13, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $126 for it. Previously, Jefferies started tracking the stock with Buy rating on May 13, 2025, and set its price target to $105. On February 25, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $100 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $48 on April 23, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $42 as its price target on February 15, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $55.
Insmed Inc [INSM] stock has fluctuated between $60.40 and $128.48 over the past year. Currently, Wall Street analysts expect the stock to reach $125 within the next 12 months. Insmed Inc [NASDAQ: INSM] shares were valued at $127.8 at the most recent close of the market. An investor can expect a potential drop of -2.19% based on the average INSM price forecast.
Analyzing the INSM fundamentals
Insmed Inc [NASDAQ:INSM] reported sales of 398.11M for the trailing twelve months, which represents a growth of 18.90%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -2.38%, Pretax Profit Margin comes in at -2.59%, and Net Profit Margin reading is -2.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.95 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 125.55 points at the first support level, and at 123.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 129.03, and for the 2nd resistance point, it is at 130.25.
Ratios To Look Out For
For context, Insmed Inc’s Current Ratio is 6.68. In addition, the Quick Ratio stands at 6.33 and the Cash Ratio stands at 4.12. Considering the valuation of this stock, the price to sales ratio is 67.85, the price to book ratio is 21.59.
Transactions by insiders
Recent insider trading involved SHAROKY MELVIN MD, Director, that happened on Aug 12 ’25 when 10000.0 shares were sold. Officer, Schaeffer Orlov S Nicole completed a deal on Aug 14 ’25 to buy 10000.0 shares. Meanwhile, Former Affiliate ALFRED ALTOMARI bought 13600.0 shares on Aug 13 ’25.
